<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Drug Policy</journal-id><journal-id journal-id-type="iso-abbrev">Int J Drug Policy</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The International journal on drug policy</journal-title></journal-title-group><issn pub-type="ppub">0955-3959</issn><issn pub-type="epub">1873-4758</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10034760</article-id><article-id pub-id-type="pmcid-ver">PMC10034760.1</article-id><article-id pub-id-type="pmcaid">10034760</article-id><article-id pub-id-type="pmcaiid">10034760</article-id><article-id pub-id-type="manuscript-id">NIHMS1874720</article-id><article-id pub-id-type="pmid">36758335</article-id><article-id pub-id-type="doi">10.1016/j.drugpo.2023.103959</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1874720</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1874720</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Predictors of Hepatitis C Cure among People Who Inject Drugs Treated with Directly Observed Therapy supported by Peer Case Managers in Kenya</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Akiyama</surname><given-names initials="MJ">Matthew J.</given-names></name><degrees>MD, MSc</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riback</surname><given-names initials="LR">Lindsey R.</given-names></name><degrees>MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nyakowa</surname><given-names initials="M">Mercy</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Musyoki</surname><given-names initials="H">Helgar</given-names></name><degrees>MPH</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lizcano</surname><given-names initials="JA">John A.</given-names></name><degrees>MPH</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Muller</surname><given-names initials="A">Abbe</given-names></name><degrees>MPH</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="C">Chenshu</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walker</surname><given-names initials="JG">Josephine G.</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stone</surname><given-names initials="J">Jack</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vickerman</surname><given-names initials="P">Peter</given-names></name><degrees>DPhil</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cherutich</surname><given-names initials="P">Peter</given-names></name><degrees>PhD, MBChB</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurth</surname><given-names initials="AE">Ann E.</given-names></name><degrees>PhD, CNM, MPH</degrees><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY</aff><aff id="A2"><label>2</label>Kenya Ministry of Health, National AIDS&amp;STI Control Program (NASCOP), Nairobi, Kenya</aff><aff id="A3"><label>3</label>Yale University School of Nursing, Orange, CT</aff><aff id="A4"><label>4</label>University of Bristol, Bristol, United Kingdom</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author Contributions:</p><p id="P2"><italic toggle="yes">Conceptualization</italic>: Akiyama, Cherutich, Kurth. <italic toggle="yes">Methodology:</italic> Akiyama, Cherutich, Kurth, Lizcano. <italic toggle="yes">Formal analysis</italic>: Zhang. <italic toggle="yes">Investigation:</italic> Akiyama, Cherutich, Kurth, Lizcano, Nyakowa. <italic toggle="yes">Resources:</italic> Musyoki. <italic toggle="yes">Data curation:</italic> Lizcano, Nyakowa, Stone, Vickerman, Walker. <italic toggle="yes">Writing - original draft</italic>: Akiyama, Riback. <italic toggle="yes">Writing - review and editing</italic>: Akiyama, Cherutich, Kurth, Lizcano, Muller, Musyoki, Nyakowa, Riback, Stone, Vickerman, Walker. <italic toggle="yes">Supervision:</italic> Akiyama, Cherutich, Kurth. <italic toggle="yes">Project administration:</italic> Lizcano, Nyakowa. <italic toggle="yes">Funding acquisition</italic>: Akiyama, Cherutich, Kurth.</p></fn><corresp id="CR1">Corresponding author: Matthew Akiyama, <email>makiyama@montefiore.org</email>, 3300 Kossuth Ave, Bronx, NY 10467, Phone: 718-405-8040, Fax: 718-405-8060</corresp><fn fn-type="COI-statement" id="FN2"><p id="P41"><bold>Conflict of Interest:</bold> No conflict declared.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>07</day><month>2</month><year>2023</year></pub-date><volume>113</volume><issue-id pub-id-type="pmc-issue-id">431871</issue-id><fpage>103959</fpage><lpage>103959</lpage><pub-history><event event-type="nihms-submitted"><date><day>26</day><month>02</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-14 04:25:15.080"><day>14</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1874720.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background &amp; Aims:</title><p id="P3">Directly observed therapy (DOT) maximizes adherence and minimizes treatment gaps. Peer case managers (PCM) have also shown promise as a component of integrated HCV treatment strategies. DOT and PCM-support have been underexplored, particularly in low- and middle-income countries (LMICs). The objective of this study was to evaluate predictors of sustained virologic response (SVR) among people who inject drugs (PWID) attending medication-assisted treatment (MAT) and needle and syringe programs (NSP) sites in Kenya.</p></sec><sec id="S2"><title>Methods:</title><p id="P4">We recruited PWID accessing MAT and NSP in Nairobi and Coastal Kenya. PWID were treated with ledipasvir/sofosbuvir using DOT supported by PCMs. We used bivariate and multivariate logistic regression to examine the impact of sociodemographic, behavioral, and clinical factors on SVR.</p></sec><sec id="S3"><title>Results:</title><p id="P5">Among 92 PWID who initiated HCV treatment, 79 (86%) were male with mean age of 36.3 years (SD=&#177;6.5); 38 (41%) were HIV-positive, and 87 (95%) reported injecting drugs in the last 30 days. Just over half of participants were genotype 1a (55%), followed by genotype 4a (41%) and mixed 1a/4a (3%). Most participants, 85 (92%) completed treatment and 79 (86%) achieved SVR. While sociodemographic and behavioral factors including recent injection drug use were not significantly associated with achieving SVR, being fully adherent (p=0.042), number of doses taken (p=0.008) and treatment completion (p= 0.001) were associated with higher odds of achieving SVR.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P6">DOT with PCM-support was an effective model for HCV treatment among PWID in this LMIC setting. Adherence was the most important driver of SVR suggesting DOT and PCM support can overcome other factors that might limit adherence. Further research is necessary to ascertain the effectiveness of other models of HCV care for PWID in LMICs given NSP and MAT access is variable, and DOT may not be sustainable with limited resources.</p></sec></abstract><kwd-group><kwd>HCV</kwd><kwd>PWID</kwd><kwd>peer</kwd><kwd>DAA</kwd><kwd>Africa</kwd><kwd>LMIC</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>